Former Chief Medical Officer · Zymeworks Inc. (ZYME)

Jeffrey Smith

FY2025 is the first fiscal year CompBrief holds for Jeffrey Smith as a named executive officer of Zymeworks; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$2,050,798

Salary $488,196Stock awards $700,660

3rd of 3 named executive officers at Zymeworks by FY2025 total.

3 named officers on file for Zymeworks, FY2025

Jeffrey Smith’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • ZYME’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Zymeworks’s whole pay program stands against its peers

  • Zymeworks’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ZYME→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed October 26, 2026 (DEF 14A).

Free

Get Jeffrey Smith’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Jeffrey Smith compensation by year

Zymeworks Summary Compensation Table · the one fiscal year held
In US dollars, as Zymeworks reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$488,196
Bonus$0
Stock awards$700,660
Option awards$649,162
Non-equity incentive$183,488
Pension and deferred compensation$0
All other$29,292
Total$2,050,798

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Zymeworks Inc. DEF 14A filed October 26, 2026, accession 0001193125-26-431936, and prior-year filings.

How this page was built: the Zymeworks Inc. filed document, accession 0001193125-26-431936. Every figure is read from that document and cited to the page and table it appears in. Filed October 26, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU53,000$1,395,490—
RSU40,000$1,053,200—
Option47,000—$8.00
Option45,000—$10.56
Option79,000—$13.22

Per the Outstanding Equity Awards at Fiscal Year-End table in Zymeworks Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Zymeworks’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Kenneth GalbraithCEO, President & Chair$6,613,180
Paul Paul A. MooreChief Scientific Officer$2,348,190
Jeffrey Smith · this pageFormer Chief Medical Officer$2,050,798

The full Zymeworks compensation record

free company brief

This page is one person within Zymeworks's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Zymeworks proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Zymeworks's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jeffrey Smith's compensation dossier · One-time report. No refunds.